NCT00165867已完成2 期
An Open Label Phase II Study of Indisulam in Combination With Irinotecan in Patients With Metastatic Colorectal Cancer Who Have Been Previously Treated With 5-Fluorouracil/Leucovorin and Oxaliplatin
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 40
- 试验地点
- 7
- 主要终点
- The objective response rate as defined by RECIST criteria.
研究概览
简要总结
The overall purpose of this study is to determine the efficacy, safety and tolerability of indisulam in combination with irinotecan as a treatment for patients with metastatic colorectalcancer previously treated with 5-fluorouracil/leucovorin and oxaliplatin (FOLFOX).
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Ambulant male or female patients with metastatic colorectal cancer who have been previously treated with 5-fluorouracil/leucovorin and oxaliplatin. Patients must fulfill the following criteria to be included in the study:
- •At least 4 doses of previous treatment with oxaliplatin
- •All previous treatment (including surgery and radiotherapy) must have been completed at least four weeks prior to study entry and any acute toxicities must have resolved
- •At least one uni-dimensionally measurable lesion according to RECIST criteria (the following do not qualify as measurable lesions: bone, leptomeningeal disease, ascites, pleural/pericardial effusion, lymphangitis cutis/pulmonis, abdominal masses that are not confirmed and followed by imaging techniques, and cystic lesions)
- •Aged greater than or equal to 18 years
- •Histologically or cytologically confirmed colorectal cancer
- •Karnofsky performance status greater than or equal to 70%
- •Written informed consent to participate in the study
排除标准
- •Patients with the following characteristics will not be included in the study:
- •More than three previous lines of chemotherapy (including neo-adjuvant and adjuvant)
- •Prior treatment with cytotoxics other than 5- fluorouracil/leucovorin (capecitabine and UFT are permitted) and oxaliplatin. Prior epidermal growth factor receptor targeted and anti-angiogenic therapy is permitted.
- •Untreated brain metastases (patients who have been treated for CNS metastases must be asymptomatic and radiologically stable for 4 weeks prior to entry). Patients must not have clinical symptoms from brain metastases and must not be taking corticosteroids for the treatment of brain metastases. Patients must not have leptomeningeal metastases
- •Any of the following laboratory parameters:
- •hemoglobin <10 g/dl;
- •neutrophils <1.5 x 109/L;
- •platelets <100 x 109/L;
- •serum bilirubin >25 mmol/l (1.5 mg/dl);
- •other liver parameters >2.5 x upper normal limit (ULN) (> 5 x upper normal limit in the presence of hepatic metastases);
- •serum creatinine >1.5 x ULN;
- •serum calcium (corrected for albumin) >=11.5 mg/dl.
- •History of Gilbert's Disease or conjugated hyperbilirubinemia
- •Concurrent or previous malignancy of a different tumor type within five years of starting the study except for adequately treated non- melanoma skin cancer or cervical intraepithelial neoplasia
- •Uncontrolled infections
- •Clinically significant cardiac impairment or unstable ischemic heart disease including a myocardial infarction within six months of study start
- •Chronic inflammatory bowel disease and/or bowel obstruction
- •History of hypersensitivity to sulfonamides
- •History of severe hypersensitivity reactions to one of the excipients of irinotecan
- •Treatment within two weeks before the start of the stud y with any of the following: coumarin anti-coagulants, terfenadine, cisapride, cyclosporin, tacrolimus, theophylline, diazepam, sulphonylurea hypoglycaemics, phenytoin, or carbamazepine
- •Any treatment with investigational drugs within 30 days before the start of the study
- •Pregnancy or lactation (all women of childbearing potential must have a negative pregnancy test before inclusion in the study; post-menopausal women must be amenorrheic for at least 12 months). Female patients must use adequate contraceptive protection
- •Fertile males not willing to use contraception or whose female partners are not using adequate contraceptive protection
- •History of alcoholism, drug addiction, or any psychiatric or psychological condition which, in the opinion of the investigator, would impair study compliance.
- •Legal incapacity
结局指标
主要结局
The objective response rate as defined by RECIST criteria.
次要结局
- Duration of response
- time to progression
- overall survival
- safety and tolerability of the combination
研究者
研究点 (7)
Loading locations...
相似试验
终止
2 期
An Open-label, Randomized, Phase II Study of the Efficacy and Safety of Indisulam (E7070) in Combination With CapecitabineMetastatic Breast CancerNCT00165880Eisai Limited62
已完成
2 期
Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Multiple Oral Bedtime Doses of ORMD-0801 in Adult Patients With Type 2 Diabetes Mellitus (T2DM)Diabetes Mellitus Type 2NCT01889667Oramed, Ltd.30
进行中（未招募）
2 期
A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of TherapiesPrimary Immune Thrombocytopenia (ITP)NCT05885555Novartis Pharmaceuticals41
已完成
2 期
Study to Evaluate Lenalidomide Plus Dexamethasone in Patients With Newly Diagnosed POEMS SyndromePOEMS SyndromeNCT01816620Peking Union Medical College Hospital41
已完成
2 期
A Safety and Tolerability Study of Belumosudil (KD025) Treatment in Subjects With Moderately Severe Psoriasis VulgarisPsoriasis VulgarisNCT02106195Kadmon Corporation, LLC8